Please wait while we load the requested 10-Q report or click the link below:
Aegerion recorded total net product sales of $35.4 million in the third quarter of 2016.
Aegerion recorded $13.4 million in net product sales of MYALEPT® (metreleptin) for injection in the third quarter of 2016, $11.9 million, or 89% of which was from prescriptions written in the United States (U.S.). Net product sales in the third quarter include a $1.0 million sale of inventory to Shionogi for distribution in Japan, South Korea and Taiwan.
As of September 30, 2016, there were approximately 125 active generalized lipodystrophy (GL) patients on commercial therapy, approximately 101 of whom are U.S. patients. In the third quarter, Aegerion began adding GL patients on commercial MYALEPT via named patient sales programs in Germany, Israel and Italy.
Aegerion recorded $22.0 million in net product sales of JUXTAPID® (lomitapide) capsules in the third quarter of 2016, $18.6 million, or 85% of which was from prescriptions written in the U.S. As of September 30, 2016, there were approximately 393 active patients on JUXTAPID therapy globally, approximately 260 of whom are U.S. patients.
In September 2016, Japan’s Ministry of Health, Labor & Welfare (MHLW) granted approval for JUXTAPID in Japan for the treatment of homozygous familial hypercholesterolemia (HoFH).
Aegerion expects to complete its merger with QLT Inc. and to submit a marketing authorization application (MAA) for metreleptin as a potential treatment for GL and a subset of partial lipodystrophy (SPL) patients in the EU in the fourth quarter of 2016.
The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Thursday, November 3, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Aegerion Pharmaceuticals, Inc..